TELIX Aktie

 

CANBERA (dpa-AFX) - Telix Pharmaceuticals Limited (TLX) has submitted a marketing authorization application in Europe for TLX101-Px, its glioma imaging candidate. The submission covers major Europ......

A key regulatory milestone has been ticked off. The post Why are Telix shares trading higher today? appeared first on The Motley Fool Australia....

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Telix submits a European application for TLX101-Px, targeting better brain cancer imaging across major markets. The post Telix Pharmaceuticals files European application for brain cancer imaging appeared first on The Motley Fool Australia....

MELBOURNE, Australia and INDIANAPOLIS, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has submitted a marketing authorization application (MAA) in Europe for TLX101-Px (O-(2-[18F]fluoroethyl)-L-tyrosine, 18F-FET), its glioma (brain cancer) imaging candidate....

Let's see what analysts are saying about these popular shares right now. The post Buy, hold, sell: CSL, Pinnacle, and Telix shares appeared first on The Motley Fool Australia....

MELBOURNE, Australia and INDIANAPOLIS, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) advises that it will release its full year results for the period ended 31 December 2025 on Friday, 20 February 2026 AEDT (Thursday, 19 February 2026 EST)....

Telix Pharmaceuticals Ltd (ASX: TLX) shares have dropped another 2.81% in Tuesday afternoon trade. At the time of writing, the … The post Will Telix shares drop below $10? appeared first on The Motley Fool Australia....

Telix Pharmaceuticals meets its FY25 revenue target with strong Q4 growth, expanded U.S. launches and ongoing trials. read more...

A leading broker expects a big rebound in Telix shares in 2026. The post Top broker tips 57% upside for beaten-down Telix shares appeared first on The Motley Fool Australia....

The PSMA-targeted therapy market is expected to grow strongly, fueled by higher prostate cancer diagnosis rates, improved awareness of PSMA-based treatments, and an expanding clinical trial landscape of therapies such as Lantheus' Lu-177-PNT2002/[Lu-177]-PSMA-I&T/PNT-2002), Telix......

More good news from the drug developer. The post Telix shares in focus as the company meets guidance appeared first on The Motley Fool Australia....

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

CANBERA (dpa-AFX) - Telix Pharmaceuticals Limited (TLX, TLX.AX) on Tuesday reported a rise in revenue for the fourth quarter, helped by increased revenue from the Precision Medicine segment and RL......

These shares are rising on Tuesday despite the market weakness. The post Why Bellevue Gold, DroneShield, Hub24, and Telix shares are storming higher today appeared first on The Motley Fool Australia....

Telix Pharma's (ASX:TLX) got the Chinese market locked in its sights with…...

The Chinese regulator has accepted the New Drug Application for Illuccix, Telix's lead imaging agent for prostate cancer. The post Telix Pharmaceuticals receives China's nod for Illuccix prostate cancer imaging NDA appeared first on The Motley Fool Australia....

Toronto (www.aktiencheck.de) - Telix Pharmaceuticals-Aktienanalyse von RBC Capital Markets: Die Analysten von RBC Capital haben die Aktie von Telix Pharmaceuticals Limited (ISIN: AU000000TLX2, WKN: A2H7JK, Ticker-Symbol: T3X, ASX-Symbol: TLX, NASDAQ OTC-Symbol: TLPPF) von "sector perform" auf "outperform" hochgestuft und das Kursziel unverändert bei 17 AUD belassen. [mehr]...

MELBOURNE, Australia, Jan. 17, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Biopsy of the Prostate Avoidance Stratification Study), a Phase 3 trial to evaluate the use of Telix's commercial PSMA-PET1 imaging agents, Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) and Gozellix® (kit for the preparation of gallium Ga 68 gozetotide injection) in the initial prostate cancer diagnosis setting. The dose was administered under the supervision of Dr. Brian Mazzarella at Urology Austin and supplied by RLS Radiopharmacies....

NEW YORK, Jan. 9, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd." or the "Company") (NASDAQ: TLX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Telix......